uniQure: The Market Graded The Wrong ExamSeeking Alpha · Oct 15, 2026
uniQure N.V. Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your QURE InvestmentsNewsfile Corp · Oct 13, 2026
uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical ReviewDefense World · Oct 8, 2026
Cedar Grove Capital Q3 2026 Portfolio UpdateSeeking Alpha · Oct 7, 2026
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share DropBusiness Wire · Oct 6, 2026
uniQure (NASDAQ:QURE) Stock Price Down 5.5% Following Analyst DowngradeDefense World · Oct 6, 2026uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 29, 2026 | -$0.82 | -$1.22 | Miss |
| May 5, 2026 | -$0.88 | -$0.85 | Beat |
| Mar 2, 2026 | -$0.93 | -$0.56 | Beat |
| Nov 10, 2025 | -$0.85 | -$1.38 | Miss |
| Jul 29, 2025 | -$0.89 | -$0.69 | Beat |
| May 9, 2025 | -$1.07 | -$0.82 | Beat |